91 filings
6-K
IMAB
I-Mab
15 Apr 24
Current report (foreign)
4:29pm
6-K
IMAB
I-Mab
2 Apr 24
I-Mab Announces Closing of the Divestiture of Business Operations in China
4:57pm
6-K
IMAB
I-Mab
1 Apr 24
Current report (foreign)
9:01am
6-K
IMAB
I-Mab
15 Mar 24
I-Mab Reports Full Year 2023 Financial Results and Business Update
6:02am
6-K
IMAB
I-Mab
7 Feb 24
I-Mab Signs Agreement
6:52am
6-K
5jz67rgbh5id b6
6 Feb 24
Current report (foreign)
6:34am
6-K
jnok3wroaph13to3
10 Oct 23
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
8:24am
6-K
w3t qakgeyka
22 Sep 23
Current report (foreign)
4:01pm
6-K
pwkz80 cgb122uyu
17 Aug 23
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
6:52am
6-K
px5f jg8uf2tr0
22 Jun 23
I-Mab Announces the Appointment of Raj Kannan as CEO
8:40am
6-K
g8kqdd1jodkrqg8b
26 May 23
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC
6:02am
6-K
68ddawl
1 May 23
Current report (foreign)
7:36am
6-K
0e7a0i4 hmxxs17
1 May 23
Current report (foreign)
7:06am
6-K
z24mxao
25 Apr 23
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
9:02am
6-K
fyux2xfkjlkl01g
25 Apr 23
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
6:01am
6-K
bewj93ikj gwap5yaqys
3 Apr 23
Current report (foreign)
6:44am
6-K
o6goccsie9
31 Mar 23
Current report (foreign)
6:53am
6-K
i7iyd6g2
10 Nov 22
Current report (foreign)
4:02pm
6-K
tipubh95wba axi
30 Sep 22
Current report (foreign)
4:02pm
6-K
jrw28
13 Sep 22
Current report (foreign)
9:13am